Ranelle Salunga
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ranelle Salunga has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Jenna Wong
Biotheranostics Inc., A Hologic Company, San Diego, California
19 shared publications - Kai Treuner
Biotheranostics, A Hologic Company, San Diego, CA, USA
19 shared publications - Yi Zhang
Biotheranostics, A Hologic Company, San Diego, CA, USA
19 shared publications - Annette Hasenburg
Department of Obstetrics and Gynecology, University Medical Center of the Johannes Gutenberg University Mainz, Langenbeckstraße, 1, 55131 Mainz, Germany
11 shared publications - Catherine A. Schnabel
BioTheranostics, Inc., San Diego, CA
11 shared publications - Christos Markopoulos
Medical School, National and Kapodistrian University of Athens, Athens, Greece
11 shared publications
Latest Publications
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Table 3 from Identification of Early-Stage Breast Cancer with a Minimal Risk of Recurrence by the Breast Cancer Index
Univariate and multivariate Fine–Gray regression analyses of BCI in the NCR cohort.
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable 3 from Identification of Early-Stage Breast Cancer with a Minimal Risk of Recurrence by the Breast Cancer Index
Univariate and multivariate Fine–Gray regression analyses of BCI in the NCR cohort.
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Figure 3 from Identification of Early-Stage Breast Cancer with a Minimal Risk of Recurrence by the Breast Cancer Index
Performance of the adjusted BCI model in the NCR cohort (A) overall and (B–D) in clinical subsets. G2/G3, grade 2/3; T1/T2, T stage 1/2.
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from Identification of Early-Stage Breast Cancer with a Minimal Risk of Recurrence by the Breast Cancer Index
Performance of the adjusted BCI model in the NCR cohort (A) overall and (B–D) in clinical subsets. G2/G3, grade 2/3; T1/T2, T stage 1/2.
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Figure 2 from Identification of Early-Stage Breast Cancer with a Minimal Risk of Recurrence by the Breast Cancer Index
Performance of the adjusted BCI model in the Stockholm cohorts. The new cutpoint for the BCI minimal-risk group was trained using the untreated patients. (A) Untreated and (B) TAM-treated. TAM, tamoxifen.
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Identification of Early-Stage Breast Cancer with a Minimal Risk of Recurrence by the Breast Cancer Index
Performance of the adjusted BCI model in the Stockholm cohorts. The new cutpoint for the BCI minimal-risk group was trained using the untreated patients. (A) Untreated and (B) TAM-treated. TAM, tamoxifen.
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Data from Identification of Early-Stage Breast Cancer with a Minimal Risk of Recurrence by the Breast Cancer Index
Purpose:This study assessed the prognostic ability of the breast cancer index (BCI) to identify patients at a minimal risk (<5%) of 10-year distant recurrence (DR) who are unlikely to benefit from adjuvant endocrine therapy.Experimental Design:This prospective translational study included postmenopausal patients with early-stage, hormone receptor–positive N0 breast cancer from the Stockholm (STO-3) trial who underwent surgery alone (“untreated”) or surgery plus adjuvant tamoxifen (“treated”) and from the Netherlands Cancer Registry (surgery alone). The primary endpoint was time to DR. An adjusted BCI model with an additional cutpoint was developed, which stratified patients into four prognostic risk groups.Results:Across cohorts, 16% to 22% of patients were classified as minimal risk of 10-year DR. In the Stockholm untreated cohort (n = 283), risks in the minimal-, low-, intermediate-, and high-risk groups were 2.3%, 15.5% [hazard ratio, 4.71 (95% confidence interval, 1.09–20.29) vs. minimal risk], 19.8% [6.97 (1.61–30.18)], and 35.9% [13.21 (3.07–56.76)], respectively (P < 0.001). In the Stockholm treated cohort (n = 317), risks were 4.3%, 5.0% [1.16 (0.35–3.85)], 11.7% [2.45 (0.74–8.14)], and 21.1% [5.27 (1.72–16.16); P < 0.001]. In the Netherlands Cancer Registry cohort (n = 1245), risks were 4.5%, 7.5% [subdistribution hazard ratio, 1.67 (95% confidence interval, 0.81–3.45)], 10.3% [2.40 (1.14–5.03)], and 13.1% [3.13 (1.50–6.55); P = 0.005]. BCI risk scores provided additional independent information over standard prognostic factors (likelihood ratio, χ2 = 7.98; P = 0.004).Conclusions:The adjusted BCI model identified women with early-stage, hormone receptor–positive N0 breast cancer at a minimal risk of DR who may consider de-escalating adjuvant endocrine therapy.
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Identification of Early-Stage Breast Cancer with a Minimal Risk of Recurrence by the Breast Cancer Index
Purpose:This study assessed the prognostic ability of the breast cancer index (BCI) to identify patients at a minimal risk (<5%) of 10-year distant recurrence (DR) who are unlikely to benefit from adjuvant endocrine therapy.Experimental Design:This prospective translational study included postmenopausal patients with early-stage, hormone receptor–positive N0 breast cancer from the Stockholm (STO-3) trial who underwent surgery alone (“untreated”) or surgery plus adjuvant tamoxifen (“treated”) and from the Netherlands Cancer Registry (surgery alone). The primary endpoint was time to DR. An adjusted BCI model with an additional cutpoint was developed, which stratified patients into four prognostic risk groups.Results:Across cohorts, 16% to 22% of patients were classified as minimal risk of 10-year DR. In the Stockholm untreated cohort (n = 283), risks in the minimal-, low-, intermediate-, and high-risk groups were 2.3%, 15.5% [hazard ratio, 4.71 (95% confidence interval, 1.09–20.29) vs. minimal risk], 19.8% [6.97 (1.61–30.18)], and 35.9% [13.21 (3.07–56.76)], respectively (P < 0.001). In the Stockholm treated cohort (n = 317), risks were 4.3%, 5.0% [1.16 (0.35–3.85)], 11.7% [2.45 (0.74–8.14)], and 21.1% [5.27 (1.72–16.16); P < 0.001]. In the Netherlands Cancer Registry cohort (n = 1245), risks were 4.5%, 7.5% [subdistribution hazard ratio, 1.67 (95% confidence interval, 0.81–3.45)], 10.3% [2.40 (1.14–5.03)], and 13.1% [3.13 (1.50–6.55); P = 0.005]. BCI risk scores provided additional independent information over standard prognostic factors (likelihood ratio, χ2 = 7.98; P = 0.004).Conclusions:The adjusted BCI model identified women with early-stage, hormone receptor–positive N0 breast cancer at a minimal risk of DR who may consider de-escalating adjuvant endocrine therapy.
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Table 2 from Identification of Early-Stage Breast Cancer with a Minimal Risk of Recurrence by the Breast Cancer Index
Prognostic performance of the four BCI risk groups in Stockholm and NCR cohorts.
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable 2 from Identification of Early-Stage Breast Cancer with a Minimal Risk of Recurrence by the Breast Cancer Index
Prognostic performance of the four BCI risk groups in Stockholm and NCR cohorts.
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Table 1 from Identification of Early-Stage Breast Cancer with a Minimal Risk of Recurrence by the Breast Cancer Index
Patient clinicopathologic characteristics in the Stockholm and NCR cohorts.
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable 1 from Identification of Early-Stage Breast Cancer with a Minimal Risk of Recurrence by the Breast Cancer Index
Patient clinicopathologic characteristics in the Stockholm and NCR cohorts.
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Figure 1 from Identification of Early-Stage Breast Cancer with a Minimal Risk of Recurrence by the Breast Cancer Index
CONSORT diagram for patient selection in the NCR cohort.
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Identification of Early-Stage Breast Cancer with a Minimal Risk of Recurrence by the Breast Cancer Index
CONSORT diagram for patient selection in the NCR cohort.
- Open Access
- 27 March 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (11) , 2222-2229
Identification of Early-Stage Breast Cancer with a Minimal Risk of Recurrence by the Breast Cancer Index
Purpose: This study assessed the prognostic ability of the breast cancer index (BCI) to identify patients at a minimal risk (<5%) of 10-year distant recurrence (DR) who are unlikely to benefit from adjuvant endocrine therapy. Experimental Design: This prospective translational study included postmenopausal patients with early-stage, hormone receptor–positive N0 breast cancer from the Stockholm (STO-3) trial who underwent surgery alone (“untreated”) or surgery plus adjuvant tamoxifen (“treated”) and from the Netherlands Cancer Registry (surgery alone). The primary endpoint was time to DR. An adjusted BCI model with an additional cutpoint was developed, which stratified patients into four prognostic risk groups. Results: Across cohorts, 16% to 22% of patients were classified as minimal risk of 10-year DR. In the Stockholm untreated cohort (n = 283), risks in the minimal-, low-, intermediate-, and high-risk groups were 2.3%, 15.5% [hazard ratio, 4.71 (95% confidence interval, 1.09–20.29) vs. minimal risk], 19.8% [6.97 (1.61–30.18)], and 35.9% [13.21 (3.07–56.76)], respectively (P < 0.001). In the Stockholm treated cohort (n = 317), risks were 4.3%, 5.0% [1.16 (0.35–3.85)], 11.7% [2.45 (0.74–8.14)], and 21.1% [5.27 (1.72–16.16); P < 0.001]. In the Netherlands Cancer Registry cohort (n = 1245), risks were 4.5%, 7.5% [subdistribution hazard ratio, 1.67 (95% confidence interval, 0.81–3.45)], 10.3% [2.40 (1.14–5.03)], and 13.1% [3.13 (1.50–6.55); P = 0.005]. BCI risk scores provided additional independent information over standard prognostic factors (likelihood ratio, χ2 = 7.98; P = 0.004). Conclusions: The adjusted BCI model identified women with early-stage, hormone receptor–positive N0 breast cancer at a minimal risk of DR who may consider de-escalating adjuvant endocrine therapy.
- 27 March 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (11) , 2222-2229
Open AccessIdentification of Early-Stage Breast Cancer with a Minimal Risk of Recurrence by the Breast Cancer Index
Purpose: This study assessed the prognostic ability of the breast cancer index (BCI) to identify patients at a minimal risk (<5%) of 10-year distant recurrence (DR) who are unlikely to benefit from adjuvant endocrine therapy. Experimental Design: This prospective translational study included postmenopausal patients with early-stage, hormone receptor–positive N0 breast cancer from the Stockholm (STO-3) trial who underwent surgery alone (“untreated”) or surgery plus adjuvant tamoxifen (“treated”) and from the Netherlands Cancer Registry (surgery alone). The primary endpoint was time to DR. An adjusted BCI model with an additional cutpoint was developed, which stratified patients into four prognostic risk groups. Results: Across cohorts, 16% to 22% of patients were classified as minimal risk of 10-year DR. In the Stockholm untreated cohort (n = 283), risks in the minimal-, low-, intermediate-, and high-risk groups were 2.3%, 15.5% [hazard ratio, 4.71 (95% confidence interval, 1.09–20.29) vs. minimal risk], 19.8% [6.97 (1.61–30.18)], and 35.9% [13.21 (3.07–56.76)], respectively (P < 0.001). In the Stockholm treated cohort (n = 317), risks were 4.3%, 5.0% [1.16 (0.35–3.85)], 11.7% [2.45 (0.74–8.14)], and 21.1% [5.27 (1.72–16.16); P < 0.001]. In the Netherlands Cancer Registry cohort (n = 1245), risks were 4.5%, 7.5% [subdistribution hazard ratio, 1.67 (95% confidence interval, 0.81–3.45)], 10.3% [2.40 (1.14–5.03)], and 13.1% [3.13 (1.50–6.55); P = 0.005]. BCI risk scores provided additional independent information over standard prognostic factors (likelihood ratio, χ2 = 7.98; P = 0.004). Conclusions: The adjusted BCI model identified women with early-stage, hormone receptor–positive N0 breast cancer at a minimal risk of DR who may consider de-escalating adjuvant endocrine therapy.
- Open Access
- 15 April 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Validation of the Prognostic Performance of Breast Cancer Index in Hormone Receptor–Positive Postmenopausal Breast Cancer Patients in the TEAM Trial
Supplemental Table 2. Distribution of patients as defined by BCI prognostic (BCI/BCIN+) and BCI predictive (BCI (H/I)).
- 15 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Validation of the Prognostic Performance of Breast Cancer Index in Hormone Receptor–Positive Postmenopausal Breast Cancer Patients in the TEAM Trial
Supplemental Table 2. Distribution of patients as defined by BCI prognostic (BCI/BCIN+) and BCI predictive (BCI (H/I)).
- Open Access
- 15 April 2024
- Published by American Association for Cancer Research (AACR)
Data from Validation of the Prognostic Performance of Breast Cancer Index in Hormone Receptor–Positive Postmenopausal Breast Cancer Patients in the TEAM Trial
Purpose:Patients with early-stage hormone receptor–positive (HR+) breast cancer face a prolonged risk of recurrence even after adjuvant endocrine therapy. The Breast Cancer Index (BCI) is significantly prognostic for overall (0–10 years) and late (5–10 years) distant recurrence (DR) risk in N0 and N1 patients. Here, BCI prognostic performance was evaluated in HR+ postmenopausal women from the Tamoxifen and Exemestane Adjuvant Multinational (TEAM) trial.Experimental Design:3,544 patients were included in the analysis (N = 1,519 N0, N = 2,025 N+). BCI risk groups were calculated using pre-specified cutoff points. Kaplan–Meier analyses and log-rank tests were used to assess the prognostic significance of BCI risk groups based on DR. Hazard ratios (HR) and confidence intervals (CI) were calculated using Cox models with and without clinical covariates.Results:For overall 10-year DR, BCI was significantly prognostic in Ni0 (N = 1,196) and N1 (N = 1,234) patients who did not receive prior chemotherapy (P < 0.001). In patients who were DR-free for 5 years, 10-year late DR rates for low- and high-risk groups were 5.4% and 9.3% (N0 cohort, N = 1,285) and 4.8% and 12.2% (N1 cohort, N = 1,625) with multivariate HRs of 2.25 (95% CI, 1.30–3.88; P = 0.004) and 2.67 (95% CI, 1.53–4.63; P < 0.001), respectively. Late DR performance was substantially improved using previously optimized cutoff points, identifying BCI low-risk groups with even lower 10-year late DR rates of 3.8% and 2.7% in N0 and N1 patients, respectively.Conclusions:The TEAM trial represents the largest prognostic validation study for BCI to date and provides a more representative assessment of late DR risk to guide individualized treatment decision-making for HR+ patients with early-stage breast cancer.
- 15 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Validation of the Prognostic Performance of Breast Cancer Index in Hormone Receptor–Positive Postmenopausal Breast Cancer Patients in the TEAM Trial
Purpose:Patients with early-stage hormone receptor–positive (HR+) breast cancer face a prolonged risk of recurrence even after adjuvant endocrine therapy. The Breast Cancer Index (BCI) is significantly prognostic for overall (0–10 years) and late (5–10 years) distant recurrence (DR) risk in N0 and N1 patients. Here, BCI prognostic performance was evaluated in HR+ postmenopausal women from the Tamoxifen and Exemestane Adjuvant Multinational (TEAM) trial.Experimental Design:3,544 patients were included in the analysis (N = 1,519 N0, N = 2,025 N+). BCI risk groups were calculated using pre-specified cutoff points. Kaplan–Meier analyses and log-rank tests were used to assess the prognostic significance of BCI risk groups based on DR. Hazard ratios (HR) and confidence intervals (CI) were calculated using Cox models with and without clinical covariates.Results:For overall 10-year DR, BCI was significantly prognostic in Ni0 (N = 1,196) and N1 (N = 1,234) patients who did not receive prior chemotherapy (P < 0.001). In patients who were DR-free for 5 years, 10-year late DR rates for low- and high-risk groups were 5.4% and 9.3% (N0 cohort, N = 1,285) and 4.8% and 12.2% (N1 cohort, N = 1,625) with multivariate HRs of 2.25 (95% CI, 1.30–3.88; P = 0.004) and 2.67 (95% CI, 1.53–4.63; P < 0.001), respectively. Late DR performance was substantially improved using previously optimized cutoff points, identifying BCI low-risk groups with even lower 10-year late DR rates of 3.8% and 2.7% in N0 and N1 patients, respectively.Conclusions:The TEAM trial represents the largest prognostic validation study for BCI to date and provides a more representative assessment of late DR risk to guide individualized treatment decision-making for HR+ patients with early-stage breast cancer.